Dipeptidyl peptidase-4 inhibitor (DPP-4i) medication increases the risk of bullous pemphigoid. In this case control study from a Finnish patient registry, conventional oral anti-diabetic medications were not associated with increased risk of bullous pemphigoid. Diabetes medications other than DDP-4i may be safe to use in patients with bullous pemphigoid.
Παρασκευή 25 Μαΐου 2018
Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: a Finnish nationwide case control study
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Small molecule inhibitor of the Wnt pathway (SM04755) as a potential topical treatment for psoriasisBackground: Psoriasis (PSO) is an autoimmune disease causing patches of thick, inflamed, scaly skin due to excessive proliferation of skin c...
-
Clinical and animal studies show that ethanol exposure and inflammation during pregnancy cause similar behavioral disturbances in the offspr...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.